Equities Analysts Set Expectations for Esperion Therapeutics, Inc.’s Q4 2025 Earnings (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Equities researchers at Zacks Research decreased their Q4 2025 earnings per share estimates for Esperion Therapeutics in a note issued to investors on Monday, April 29th. Zacks Research analyst K. Das now expects that the biopharmaceutical company will post earnings per share of $0.14 for the quarter, down from their prior forecast of $0.17. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.68) per share. Zacks Research also issued estimates for Esperion Therapeutics’ Q1 2026 earnings at $0.51 EPS and FY2026 earnings at $1.81 EPS.

A number of other research analysts have also recently issued reports on ESPR. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research note on Monday, March 25th. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price objective on shares of Esperion Therapeutics in a research note on Wednesday, April 10th. Finally, Bank of America cut Esperion Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, January 3rd. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $9.33.

Esperion Therapeutics Stock Performance

NASDAQ ESPR opened at $1.97 on Wednesday. The stock’s 50-day simple moving average is $2.37 and its two-hundred day simple moving average is $2.02. Esperion Therapeutics has a twelve month low of $0.70 and a twelve month high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR) last released its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.03. The firm had revenue of $32.25 million for the quarter, compared to analysts’ expectations of $26.84 million. During the same quarter in the previous year, the business earned ($0.76) EPS.

Institutional Trading of Esperion Therapeutics

Several large investors have recently modified their holdings of the business. Mesirow Financial Investment Management Inc. bought a new stake in shares of Esperion Therapeutics in the first quarter worth about $54,000. Summit Financial LLC grew its stake in shares of Esperion Therapeutics by 66.8% in the first quarter. Summit Financial LLC now owns 25,864 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 10,355 shares during the last quarter. Simplicity Wealth LLC bought a new stake in shares of Esperion Therapeutics in the first quarter worth about $44,000. Herbst Group LLC bought a new stake in shares of Esperion Therapeutics in the first quarter worth about $28,000. Finally, Wasatch Advisors LP grew its stake in shares of Esperion Therapeutics by 2.7% in the first quarter. Wasatch Advisors LP now owns 9,129,647 shares of the biopharmaceutical company’s stock worth $24,467,000 after purchasing an additional 238,544 shares during the last quarter. 47.39% of the stock is owned by institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.